North America Human Insulin Drugs Market Insights Forecasts to 2033

• The North America Human Insulin Drugs Market Size was valued at USD 11.14 Billion in 2023.
• The Market is Growing at a CAGR of 4.1% from 2023 to 2033
• The North America Human Insulin Drugs Market Size is Expected to Reach USD 16.65 Billion by 2033

The North America Human Insulin Drugs Market Size is Anticipated to Reach USD 16.65 Billion by 2033, Growing at a CAGR of 4.1% from 2023 to 2033.

Market Overview

A human insulin drug is a synthetic version of the hormone insulin that is structurally identical to insulin produced by the human pancreas. Human insulin drug is used to regulate blood sugar levels in diabetics, helping to manage their condition by facilitating glucose uptake into cells and thus lowering blood glucose levels. This synthetic insulin mimics the effects of the natural hormone, allowing diabetics to keep their blood sugar levels stable and healthy. Advancements such as the introduction of long-acting, rapid-acting, and pre-mixed analog insulin have given physicians and patients more flexibility and better options for blood glucose management. Also, improvements in insulin delivery systems such as insulin pens and pumps, which deliver small and precise doses of human insulin drugs, have resulted in better outcomes. The implementation of supportive government policies to increase awareness of diabetes treatment and provide access to high-quality healthcare facilities contributes to market growth.

Report Coverage

This research report categorizes for the North America human insulin drugs market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the North America human insulin drugs market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the North America human insulin drugs market.

Driving Factors

An increase in the prevalence of Type 2 diabetes cases boosts the Noth America human insulin drugs market. The market for Type 2 Diabetes Mellitus is expected to grow due to an increase in insulin-focused R&D activities. One such example is the collaboration between Cleveland Clinic, a non-profit academic medical center, and Novo Nordisk A/S, a global healthcare company, which will begin research in September 2020. The study aims to determine if once-weekly subcutaneous semaglutide combined with once-daily insulin degludec, basal insulin, can maintain or improve glycemic control in Type 2 Diabetes Mellitus patients with adequate glycemic control (≤7.5%) by replacing multiple daily insulin injections.

Restraining Factors

The human insulin drug market's growth is likely to be hampered by rising insulin prices. This is due to the fact that the cost of insulin has risen significantly over time, resulting in a doubling of out-of-pocket prescription costs for patients.

Market Segmentation

The North America human insulin drugs market share is classified into product and application

• The basal insulin segment is expected to hold the largest market share through the forecast period.

The North America human insulin drugs market is segmented by product into human insulin, basal insulin, bolus insulin, insulin combinations, and biosimilar insulins. Among these, the basal insulin segment is expected to hold the largest market share through the forecast period. This is because several pharmaceutical companies have introduced new products. Novo Nordisk, for example, has recently introduced unbranded versions of Tresiba analog insulin. This development is expected to improve patients' access to more affordable insulin options. Tresiba is an ultralong-acting basal insulin analogue known as insulin degludec. It was approved by the US Food and Drug Administration (FDA).

• The product I diabetes segment is expected to dominate the North America human insulin drugs market during the forecast period.       

Based on the application, the North America human insulin drugs market is divided into product I diabetes, and product II diabetes. Among these, the product I diabetes segment is expected to dominate the North America human insulin drugs market during the forecast period. Type 1 diabetes is considered a more serious condition than type 2. Type 2 diabetes has a high global prevalence, making it the market's fastest-growing segment.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the North America human insulin drugs market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Novo Nordisk A/S
• Sanofi S.A.
• Eli Lilly and Company
• Biocon Limited
• Pfizer Inc.
• Wockhardt
• Julphar
• Sedico
• Tonghua Dong Bao Pharmaceutical Co. Inc.
• Bristol-Myers Squibb Company
• GlaxoSmithKline Plc
• Oramed pharmaceutical
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at France, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the North America human insulin drugs market based on the below-mentioned segments:

North America Human Insulin Drugs Market, By Product

• Human Insulin
• Basal Insulin
• Bolus Insulin
• Insulin Combinations
• Biosimilar Insulins

North America Human Insulin Drugs Market, By Application

• Product I Diabetes
• Product II Diabetes